Trinity Biotech revenues up 20% for Q2

Trinity Biotech’s revenues for the three months to June 30, 2006, increased by 20.3% to $27.3m (€21.2m) compared with the same period in 2005.

Profit for the period increased from $1.1m (€853,700) in Q2 2005 to $2.1m (€1.6m) before an inventory write-off in Q2 2006, representing an increase of 95%.

The once-off write-off of $5.8m (€4.5m) is primarily attributable to the discontinuation of various product lines following the acquisition of the bioMerieux haemostasis business in June.